Prestige Consumer Healthcare Inc.

Is Prestige Consumer Healthcare publicly traded?
Yes. Prestige trades on the New York Stock Exchange under ticker PBH, with institutional investors holding the majority of shares.

What brands does Prestige own?
Its portfolio includes Clear Eyes, Dramamine, Monistat, Chloraseptic, Summer's Eve, Compound W, FiberCon, Beano, Fleet, DenTek, and Luden's, among other OTC brands.

When was Prestige founded?
The company was formed in 1999 through the consolidation of small OTC businesses including Medtech Labs. It renamed itself Prestige Consumer Healthcare in 2018.

How big is Prestige?
Prestige generates approximately $1.1 billion in annual revenue for its fiscal year ending March 2025 and employs about 600 people, an unusually lean operation reflecting outsourced manufacturing.

Does Prestige own FiberCon?
Yes. FDA labeling effective mid-2026 identifies Medtech Products Inc., a Prestige subsidiary, as the distributor of FiberCon, and the brand's website confirms Prestige operation.

Where is Prestige headquartered?
Prestige Consumer Healthcare is headquartered in Tarrytown, New York, in Westchester County north of New York City.

Prestige Brands Holdings was formed in the late 1990s through the consolidation of several small OTC businesses, including Medtech Labs and related consumer health assets. The founding concept was to acquire mature OTC brands being divested by large pharmaceutical companies and run them profitably at smaller scale.

Through the 2000s, the company built its portfolio through acquisitions. A landmark 2005 deal brought Monistat, e.p.t, and related women's health brands from Johnson & Johnson. Additional acquisitions assembled a broad OTC portfolio spanning eye care, cough and cold, digestive health, and dermatology.

The company went public on the New York Stock Exchange under ticker PBH, using its cash-generative, low-capital model to fund continued brand acquisitions. In 2018, it renamed itself Prestige Consumer Healthcare Inc. to reflect its focus on consumer health categories.

During the 2010s and 2020s, Prestige continued tuck-in acquisitions and occasionally divested brands to optimize the portfolio. The 2026 shift of FiberCon distribution to its Medtech Products subsidiary added the fiber laxative to its digestive health lineup alongside Dramamine and Beano.

The company has maintained consistent mid-single-digit organic growth and high margins relative to larger consumer health companies, making it a steady performer in the OTC sector.

Prestige operates under standard FDA OTC monograph regulations, and its products carry required labeling and warnings. The company has faced no major regulatory action or product safety crisis in recent years.

Like all OTC companies, it is exposed to periodic FDA manufacturing compliance reviews and to litigation over product claims, but no significant adverse ruling was on public record as of November 2026.

Its Monistat and feminine care brands have at times drawn consumer attention to formulation and marketing, handled through standard regulatory channels. The company's low public profile keeps it out of the broader controversies affecting larger consumer health companies.